Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report

Egle Corrado; Antonino Saladino; Giusy Morgante; Antonino Mignano; Cinzia Nugara; Giuseppina Novo; Giuseppe Coppola

doi:10.1002/ccr3.2655

Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report

Clin Case Rep. 2020 Jun 9;8(8):1349-1352. doi: 10.1002/ccr3.2655. eCollection 2020 Aug.

Authors

Egle Corrado¹, Antonino Saladino¹, Giusy Morgante¹, Antonino Mignano¹, Cinzia Nugara¹, Giuseppina Novo¹, Giuseppe Coppola¹

Affiliation

¹ UTIC - Cardiologia Policlinico Universitario Paolo Giaccone Palermo Italy.

Abstract

Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.

Keywords: ARNI; arrhythmic burden; heart failure; remodeling.

Publication types

Case Reports